ClinicalTrials.Veeva

Menu

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Sarcoma Alliance for Research through Collaboration logo

Sarcoma Alliance for Research through Collaboration

Status and phase

Terminated
Phase 3

Conditions

Gastrointestinal Stromal Tumors

Treatments

Drug: Imatinib mesylate

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01031628
STI571BUS286T
SARC019

Details and patient eligibility

About

The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • Unresectable and/or metastatic GIST
  • Currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to registration, and for no more than 6 months prior to registration. This must be the first time that the patient has been treated for metastatic and/or unresectable GIST
  • For patients who received imatinib following surgery at the time of an initial diagnosis of GIST, there must be a 6 month interval between completion of imatinib and the diagnosis of metastatic GIST
  • Good physical functioning (ECOG Performance Status of 0 or 1)
  • Generally, good function of organ such as liver and kidneys

Exclusion criteria

  • Disease progression during adjuvant therapy with imatinib (adjuvant treatment is treatment that is given after surgery for GIST)
  • Known intolerance of imatinib at a dose of 400 mg/day or higher
  • Prior systemic therapy for advanced GIST with imatinib or those who have been on imatinib for longer than 6 months for unresectable and/or metastatic disease
  • Major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered from prior surgery
  • Use of coumadin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)
  • Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks or who have not recovered from side effects of this therapy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

5 participants in 4 patient groups

Arm A
Active Comparator group
Description:
Patients with blood level less than 1100 will continue imatinib 400 mg daily
Treatment:
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Arm B
Active Comparator group
Description:
Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
Treatment:
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Arm C
Active Comparator group
Description:
Patients with blood level ≥1100 will continue imatinib 400 mg daily
Treatment:
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Arm D
Active Comparator group
Description:
Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
Treatment:
Drug: Imatinib mesylate
Drug: Imatinib mesylate
Drug: Imatinib mesylate

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems